Doctor's Bio
Board-certified in medical oncology, hematology, and internal medicine, Dr. Morgan L. McLemore, MD, has an active basic research laboratory focusing on myeloid differentiation. Dr. Morgan L. McLemore is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University. He is also a member of the American Society of Hematology.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: University of Texas Medical School at San Antonio
- Residency: Washington University School of Medicine
Fellowships
Washington University School of Medicine
Locations and Directions
Grady Memorial Hospital
Phone: (404) 616-1000
Location:
80 Jesse Hill Jr Drive SE
Atlanta, GA 30303
Publications
- Langerhans Cell Histiocytosis With Hypothalamic-pituitary and Bone Involvement: A Report of 2 Cases.
Giraldi EA, Allen JW, McLemore ML, Ioachimescu AG
JCEM case reports. 2025;3(3):luaf017.
PMID: 39935495 - The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center.
Afranie-Sakyi JA, Randall E, Fasano R, McLemore ML, El Rassi F
European journal of haematology. 2025;114(4):663-671.
PMID: 39748504 - Characteristics of Emergency Department Visits Made by Individuals With Sickle Cell Disease in the U.S., 1999-2020.
Attell BK, Barrett PM, Pace BS, McLemore ML, McGee BT, Oshe R, DiGirolamo AM, Cohen LL, Snyder AB
AJPM focus. 2024;3(1):100158.
PMID: 38149076 - Adult-onset Langerhans cell histiocytosis of bone: A case series highlighting a rare entity.
Javadi T, Hill C, McLemore ML, Oskouei S, Bahrami A
Annals of diagnostic pathology. 2023;
PMID: 37295039 - Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
Nakahara H, Cheedarla N, Verkerke HP, Cheedarla S, Wu SC, Hendrickson JE, Chang A, McLemore ML, El Rassi F, Roback JD, Neish AS, Fasano RM, Stowell SR
British journal of haematology. 2023;202(5):937-941.
PMID: 37287128 - Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK
JCO oncology practice. 2021;17(4):e497-e505.
PMID: 33125295 - Extreme hyperbilirubinemia: An indicator of morbidity and mortality in sickle cell disease.
Haydek JP, Taborda C, Shah R, Reshamwala PA, McLemore ML, Rassi FE, Chawla S
World journal of hepatology. 2019;11(3):287-293.
PMID: 30967906 - Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM
Transfusion. 2019;59(5):1698-1705.
PMID: 30848512 - Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia.
Chonat S, McLemore ML, Bunting ST, Nortman S, Zhang K, Kalfa TA
British journal of haematology. 2018;182(1):10.
PMID: 29676459 - Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ
Clinical lymphoma, myeloma & leukemia. 2017;17(12):e71-e73.
PMID: 29032022
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.